April 15, 2020 Douglas S. Ingram President and Chief Executive Officer Sarepta Therapeutics, Inc. 215 First Street, Suite 415 Cambridge, MA 02142 Re: Sarepta Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 8, 2020 File No. 001-14895 Dear Mr. Ingram: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Raymond J. Grant, Esq.